| Ezetimibe effect on bone mineral density and markers of bone formation and resorption. | |
| | |
MedLine Citation:
|
PMID: 20009956 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Ezetimibe, as a lipid-lowering agent, inhibits the intestinal absorption of cholesterol and decreases low-density lipoprotein cholesterol (LDL-C) level in serum. It also up-regulates hepatic cholesterol biosynthesis and, by contrast to statins, increases serum mevalonate levels. Statins and biphosphonates decrease osteoclastic activity through the same mechanisms by inhibiting the mevalonate pathway. We therefore tested the effect of ezetimibe on bone turnover in hypercholesterolemic patients. SUBJECT AND METHODS: In an open-label clinical trial, 54 hypercholesterolemic patients included in the study underwent 12 months of treatment with ezetimibe at a dosage of 10 mg/d. Before and after the 1-year ezetimibe treatment, bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry and serum samples taken for measurements of levels of total cholesterol (TC), triglyceride, high-density lipoprotein cholesterol and LDL-C, serum calcium (Ca), serum phosphate, total and bone alkaline phosphatases (ALPs), and carboxyterminal fragment of type 1 collagen in the serum. RESULTS: The hypercholesterolemic patients showed a significant reduction with respect to baseline TC and LDL-C serum levels: 20% for TC (270.18 [38.58]-214.46 [38] mg/dL) and 24% for LDL-C (189.57 [38.58]-144 [32.05] mg/dL). Biochemical markers of both bone formations (total ALP level, 65.50 [21.33]-66.27 [21.017] IU/L and bone ALP level, 55.93 [7.92]-56.25 [7.49] IU/L) and bone resorption (beta-CTx, 0.44 [0.24]-0.46 [0.21] ng/mL) increased but did not show any significant change for the whole study period. At the end of 1 year, both BMD-lumbar spine (0.90 [0.12]-0.89 [0.08] g/cm) and BMD-total femur (0.93 [0.12]-0.92 [0.12] g/cm) showed a negative trend but without reaching statistical significance. CONCLUSIONS: Our study results showed a negative trend but did not demonstrate statistically significant changes of BMD and metabolic markers with the treatment of ezetimibe. |
| | |
Authors:
|
Yasar Sertbas; Ugur Ersoy; Meltem Ayter; Filiz Gultekin Tirtil; Belgin Kucukkaya |
Related Documents
:
|
8039436 - Circadian and circatrigintan changes in osteoblastic activity assessed by serum osteoca... 10920216 - Bone mass and markers of bone and calcium metabolism in postmenopausal women treated wi... 1932386 - Serum alpha 2-hs-glycoprotein levels in neonatal infections. 18299476 - Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappab... 6152966 - Short-term kinetics of serum adrenal steroids and plasma acth after a single dose of me... 3972336 - Fate of parathyroid hormone during hemodialysis and ultrafiltration. |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Journal of investigative medicine : the official publication of the American Federation for Clinical Research Volume: 58 ISSN: 1708-8267 ISO Abbreviation: J. Investig. Med. Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-02-04 Completed Date: 2010-04-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9501229 Medline TA: J Investig Med Country: Canada |
Other Details:
|
Languages: eng Pagination: 295-7 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, Fatih Sultan Mehmet Education and Research Hospital, Bostanci-Kadikoy, Istanbul, Turkey. ysertbas@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alkaline Phosphatase
/
blood Anticholesteremic Agents / adverse effects* Azetidines / adverse effects* Biological Markers / blood Bone Density / drug effects* Bone Remodeling / drug effects* Collagen Type I / blood Female Humans Hypercholesterolemia / drug therapy, metabolism Lipids / blood Male Peptide Fragments / blood |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Azetidines; 0/Biological Markers; 0/Collagen Type I; 0/Lipids; 0/Peptide Fragments; 163222-33-1/ezetimibe; EC 3.1.3.1/Alkaline Phosphatase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Emotional Stress and Tako-Tsubo Cardiomyopathy: Observations on 2 Distinct Clinical Phenotypes.
Next Document: A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case se...